<DOC>
	<DOC>NCT03062397</DOC>
	<brief_summary>Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Subjects with acute ischemic stroke, aging â‰¥ 19 Confirmed to have acute anterior circulation cerebral artery occlusion in intracranial internal carotid artery (IICA) or middle cerebral artery (MCA) M1 segment by CT or MR angiography. National Institutes of Health Stroke Scale(NIHSS) is 6~30 before endovascular recanalization therapy (ERT) Subject who is reperfused with 2b or 3 stages of thrombolysis in cerebral infarction (TICI) (However, if angiography is conducted for thrombectomy after IV tPA treatment and the effect of tPA results in TICI 2b3 reperfusion, the subject can participate) Subject who can administer IP within 6.5 hrs of symptom development Subject who can administer IP within 30 min of vascular reperfusion Subject who can evaluate MRI within 90 min of vascular reperfusion Subject who is contraindicated for endovascular recanalization Subject who has hypersensitivity to contrast agent or component of investigational product Prohibited or unable to perform MRI test Medical history that is related to bleeding History of hemorrhagic stroke within 6 months of study participation Subjects with chronic liver disorder Kidney disorder (Serum creatinine &gt; 3 mg/dL) Life expectancy is less than 3 months due to concomitant disease other than stroke Pregnant or lactating women Those who have taken tirofiban (anticoagulant agent) during endovascular recanalization therapy Those who have taken other investigational drugs and/or medical instruments 12 weeks prior to screening Subject is unable to be followed up Subject is deemed unable to participate the study in the opinion of the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>